CCND2 and breast cancer: For BPB, the highest (vs. lowest) quantile was associated with a decreased odds of hypermethylated CCND2 promoter‐defined BC (OR = 0.48, 95% CI = 0.25–0.93; CLR = 3.72) versus controls, and with an OR of hypomethylated CCND2 promoter‐defined BC close to one (OR = 0.98, 95% CI = 0.70–1.37; CLR = 1.96).